Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Anamorelin (Primary)
- Indications Anorexia; Cachexia
- Focus Therapeutic Use
- Sponsors Helsinn Therapeutics; Sapphire Therapeutics
- 28 Nov 2013 New trial record
- 11 Nov 2013 Data have been presented at the 2013 European Cancer Congress (Abstract number: 1308), according to a Helsinn media release.